Celltrion Remsima Is No. 1 in Domestic Drug Production in 2023…The 2nd place is?
Jan 08, 2025
|
According to the Ministry of Food and Drug Safety, the intravenous formulation of autoimmune disease treatment biosimilar (biopharmaceutical replication drug) Remsima Ju 100 mg in 2023 was 230 billion won, up about 26% from the previous year. Dong-A ST's growth hormone product 'Grotropin-to-injection solution cartridge' was about 150 billion won, and LG Chem's growth hormone product 'Utropin-Penju' was followed by 140 billion won, respectively. The drug that ranked first and second in production in 2022 was Moderna Korea's 'Spikebox Ju'.
According to the total amount of pharmaceutical production by domestic pharmaceutical companies in 2023, Celltrion ranked first with about 1.5 trillion won, up about 27% from the previous year. It was followed by Hanmi Pharmaceutical (about 1.3 trillion won) and Chong Kun Dang (about 1.1 trillion won).
Celltrion maintained its No. 1 position in 2020-2021 and lost its No. 1 position to Moderna Korea in 2022. Moderna Korea (approximately 1.3 trillion won), Celltrion (approximately 1.2 trillion won), and Hanmi Pharmaceutical (approximately 1.2 trillion won) were ranked in the order of production volume of pharmaceutical companies in 2022. Hanmi Pharmaceutical's drug production increased by about 6.4% year-on-year in 2023 and Chong Kun Dang's production increased by 3.6%. Daewoong Pharmaceutical and Yuhan Corporation also increased by about 11.4% and 42.5% during the same period.
This article was translated by Naver AI translator.
